CN102205011A - Medicinal composition with weight loss function - Google Patents
Medicinal composition with weight loss function Download PDFInfo
- Publication number
- CN102205011A CN102205011A CN2011101367029A CN201110136702A CN102205011A CN 102205011 A CN102205011 A CN 102205011A CN 2011101367029 A CN2011101367029 A CN 2011101367029A CN 201110136702 A CN201110136702 A CN 201110136702A CN 102205011 A CN102205011 A CN 102205011A
- Authority
- CN
- China
- Prior art keywords
- extract
- carnitine
- tea polyphenols
- rhizoma alismatis
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal composition with weight loss function. The medicinal composition is an oral preparation prepared from L-carnitine, an alisma extract, a gynostemma liquidum extract, tea polyphenol and a lotus leaf extract, which serve as the active ingredients. The medicinal composition is safe and non-toxic and has the effect of losing weight.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to the Chinese medicine preparation of weight losing function.
Background technology
Now, obesity becomes the popular chronic disease of modern society that threatens human health day by day.Overweight and obesity are to cause the important root of numerous disease, fat except influencing physical and mental health, it can cause or bring out cholelithiasis, diabetes, hyperlipemia, hypertension, cerebrovascular disorders, angina pectoris and myocardial infarction etc., also easily causes suffering from kind of complication surplus multiple cancer, cholecystitis, the respiratory system disease etc. 30.Obesity is considered to a kind of chronic disease, is difficult to cure, and develops at present and just with surprising rapidity, has become the public health problem in the global range.Therefore obesity is human health life-prolonging formidable enemy.The medicine and the health food of exploitation treatment and prevention of obesity have very important significance.
Summary of the invention
The objective of the invention is in order to overcome the deficiency in the background technology, and a kind of good effect, the instant effect of development and the pharmaceutical composition with weight losing function that has no side effect.
The inventor is in tcm clinical practice and drug research decades, and the treatment patient has invented this combination of oral medication up on ten thousand person-times of bases surplus 20.
To achieve these goals, the technical solution used in the present invention is: a kind of pharmaceutical composition with weight losing function, said preparation are to be the oral formulations that composition is made with L-carnitine, Rhizoma Alismatis extract, Herb Gynostemmae Pentaphylli extract, tea polyphenols, Folium Nelumbinis extract; Wherein compositions composition percentage by weight consists of: L-carnitine 10-50%, Rhizoma Alismatis extract 5-30%, Herb Gynostemmae Pentaphylli extract 10-50%, tea polyphenols 5-30%, Folium Nelumbinis extract 5-30%.
Optimized technical scheme of the present invention is, a kind of pharmaceutical composition with weight losing function, it is characterized in that primary raw material consists of: L-carnitine 20-35%, Rhizoma Alismatis extract 5-10%, Herb Gynostemmae Pentaphylli extract 10-20%, tea polyphenols 10-15%, Folium Nelumbinis extract 5-15%.
The wherein said oral formulations of the present invention comprises tablet, capsule, granule or oral liquid for various dosage forms medically.Chinese drug-treated group composition extract mixes, and operational approach and pharmaceutic adjuvant are made tablet, capsule, granule, drop pill or oral liquid routinely.
Described pharmaceutical composition is used in the health food of preparation weight losing function.
Preparation active ingredient quantitative criterion total saponins of the present invention is measured 120g/100g according to the method for " mensuration of total saponins in the health food " in " health food check and assessment technique standard " (version in 2003); Tea polyphenols carries out according to the related request of " QB 2154-1995 food additive tea polyphenols ", tea polyphenols 10.0g/100g, and carnitine carries out 20.0g/100g according to the related request of " GB 17787-1999 food additive L-carnitine ".
The present invention to the oral dose of weight losing function Chinese medicine preparation is: 3-4g/ day.30 days courses of treatment.
Chinese medicine belongs to obesity categories such as " phlegm-damp ", " turbid resistance ", " congestion ", belongs to deficiency in origin and excess in superficiality more.Chinese medicine thinks that its generation is relevant with factors such as age, diet, heredity, body constitution, and is dirty in close relations with liver,spleen,kidney three.
Use dampness removing in the Chinese medicine in the present invention prescription, change turbid, the Rhizoma Alismatis extract of blood fat reducing, the QI invigorating tonify deficiency, the blue extract of thigh strand of heat-clearing and toxic substances removing, QI invigorating tonify deficiency, three Chinese medicines of the Folium Nelumbinis extract of heat-clearing and toxic substances removing; Be aided with and suppress the body fat deposition in the modern pharmacological research and promote that superabundant fats decomposes tea polyphenols and quickens the burning of fatty acid in the body, control lipometabolic L-carnitine.All flavor compatibilities, according to traditional Chinese medical science invigorating spleen to remove dampness, QI invigorating tonify deficiency, change the principle of turbid blood fat reducing, heat-clearing and toxic substances removing, this prescription can effectively be prevented and treated hyperlipemia, fat and concurrent disease.Modern pharmacology studies show that this prescription has blood fat reducing, the effect of fat-reducing.
Among the we, L-carnitine is a kind of very important " condition nutritional factors ", is the solvent of microorganism, animal and plant.In mammalian body, L-carnitine is synthetic in kidney, liver by methionine and lysine, is present in a large number in skeletal muscle, cardiac muscle and the epididymis.L-carnitine is a kind of chemical compound with different physiological roles, its main function is to be transported to long-chain fatty acid in the film outside mitochondrial membrane as carrier with the form of fatty acyl carnitine, in mitochondrion, carry out beta oxidation, thereby produce power is to keep body temperature, muscle work done, peristalsis of the digest tract etc.Therefore the concentration of carnitine is the lipometabolic key factor of control.The L-carnitine of high concentration can quicken the burning of fatty acid, reduces the ratio of S-acetyl-coenzyme-A/coenzyme A in the mitochondrion simultaneously, promotes the catabolism of fat indirectly.
Rhizoma Alismatis, sweet in the mouth, cold in nature, return kidney, urinary bladder channel, have dampness removing, change effect turbid, blood fat reducing.Cure mainly dysuria, the puckery pain of pyretic stranguria, the edema distension is had loose bowels, dizziness due to fluid-retention etc.Contain multiple tetracyclic triterpene keto-alcohol derivant in the Rhizoma Alismatis, sesquiterpenoids and multiple trace element with physiologically active.Modern medicine study, Rhizoma Alismatis can reduce serum total cholesterol and triacylglycerol content, slow down atherosclerosis and form.Rhizoma Alismatis extract can significantly suppress the formation of the interior speckle of experimental hyperlipidemia man's rabbit aorta, and is not obvious to low-density ester gp cholesterol level in the reduction blood.Rhizoma Alismatis effect for reducing fat and the exogenous cholesterol of its inhibition, triacylglycerol absorbs, and influences the endogenous cholesterol metabolism and suppresses synthetic relevant in the triacylglycerol liver.Evidence, Rhizoma Alismatis has antiobesity action: Rhizoma Alismatis water decoction feed has antiobesity action to the obesity that heavy dose of sodium glutamate causes, reduces the Lee exponential quantity of obese rat, fat index and serum triacylglycerol content around uterus and the testis.
Herb Gynostemmae Pentaphylli, bitter in the mouth, little sweet, cold in nature, return lung, spleen, kidney channel.Function cures mainly QI invigorating tonify deficiency, heat-clearing and toxic substances removing.It is weak to be used for body void, nephrasthenia emission, leukopenia, hyperlipemia, viral hepatitis, chronic gastroenteritis, chronic tracheitis.Modern pharmacology is found, Herb Gynostemmae Pentaphylli not only can suppress the rising of T-CHOL and triglyceride in the high fat animal serum, and can reduce low-density lipoprotein cholesterol (LDL), increase HDL-C (HDL), HDL/LDL ratio is increased, imbalance improves significantly and regulating action to lipid metabolism, and it transfers the fat effect to produce free fatty with the inhibition adipose cell and synthetic neutral fat is relevant.
Tea polyphenols has another name called tea tannin, tea polyphenols, is the All Pure Nature antioxidant food that extracts from Folium Camelliae sinensis, and based on catechin, by the hydroxyl phenolic compound that multiple aldehydes matter is formed, it is strong to have oxidation resistance, has no side effect characteristics such as free from extraneous odour.The tea polyphenols antiobesity action mainly decomposes by superabundant fats in inhibition body fat deposition and the promotion body to be realized.Tea polyphenols can suppress the overexpression of the key enzyme fatty acid synthetase (FAS) of synthetic endogenous triacylglycerol (TG), thereby suppresses effect of TG biosynthesis and proliferation function in the adipose cell at protein and mRNA level, shows effect of weight reducing.Discovery tea polyphenols such as Chan can influence the absorption of fat in the meals, have quickened fatty acid and have discharged in body, and the raw material that causes for the synthetic TG of body reduces, and has reduced the level of TG in the serum.
Folium Nelumbinis, bitter, flat, return liver, spleen, stomach warp, function clearing away summer-heat, sending up the lucid YANG, cooling blood for hemostasis clinically are used for that summer-heat excessive thirst, diarrhea due to summer heat and dampness, heat in blood are told nosebleed, the metrorrhagia of having blood in stool, and mainly contain compositions such as alkaloid, flavone, quintessence oil, vitamin C, organic acid.Studies show that in recent years, Folium Nelumbinis extract has functions of lowering blood-fat and reducing weight.Zoopery is the result show: Folium Nelumbinis extract has obvious regulating action to the high blood lipid model rat, and along with the increase of dosage, the reduction of TG content is remarkable.
Make a general survey of all medicine compatibilities of the present invention, play the effect of fat-reducing altogether, have weight losing function.
Pharmacological evaluation:
All pharmaceutical compositions with weight losing function of preparation of the present invention be (the fine graceful capsule of Sheng Kang source, land board) it have the function of fat-reducing, observe through the mice fat animal model and find all can significantly alleviate simple fat model mice body weight and reduce the mouse web portion fat mass.Select the Wistar male rat for use, the feed high lipid food is set up preventative fat high blood lipid model.The rat random packet, with 25mg/kg, 50 mg/kg, basic, normal, high three dosage of 50 mg/kg (be equivalent to human body recommended amounts 5,10,20 times), gastric infusion 30 days, other establishes normal group distilled water negative control.Measure normal group, model group, the body weight numerical value of administration experimental group rat, fatty weight in wet base.
Table 1 experiment forebody-afterbody remeasurement result (x ± s)
| Group | Before the test | After the test |
| Normal group | 170.1±15.5 | 200.4±8.1 |
| Model group | 247.4±18.5 | 265.9±45.5 |
| Low dose group | 235.5±31.2 | 234.3±38.5 |
| Middle dosage group | 237.6±26.1 | 223.9±19.2 |
| High dose group | 240.1±43.2 | 218.5±42.8 |
From last table, middle dosage group, high dose group average weight are starkly lower than model control group, with model control group significant difference (P＜0.05) are arranged relatively, with positive controls there was no significant difference (P〉0.05) relatively; But low dose group body weight and model control group are relatively, and difference does not have significance (P〉0.05).
Each reagent group of table 2 is to the influence of obese rat internal organs and fatty tissue weight (x ± s)
| Group | Liver/body weight (* 100) | Kidney/body weight (* 100) | Spleen/body weight (* 100) | Fat weight in wet base/body weight (* 100) |
| Normal group | 2.87±0.44 | 0.58±0.04 | 0.33±0.1 | 1.17±0.57 |
| Model group | 3.68±0.45 | 0.55±0. 4 | 0.29±0.07 | 7.26±2.05 |
| Low dose group | 3.88±0.32 | 0.64±0.09 | 0.38±0.16 | 4.08.3±1.15 |
| Middle dosage group | 3.82±0.95 | 0.53±0.21 | 0.33±0.11 | 3.92±1.18 |
| High dose group | 3.55±0.51 | 0.68±0.15 | 0.37±0.09 | 3.01±1.18 |
Found out by table 2: each the internal organs ratio and the model control value of each medicine group have certain difference, but difference does not have significance (P〉0.05).The fatty weight in wet base of each dosage group all descends to some extent than model control group, and difference has significance (P＜O.05), but the proportion of the liver,kidney,spleen of each dosage group and body weight and model group are relatively and there was no significant difference.This invention has the function of fat-reducing, and obesity, hyperlipidemia are had good preventing and therapeutical effect.
Human trial:
Adopt double-blind method, simple overweight people volunteer 110 examples that will meet total fatty percentage rate male＞25%, women＞30% after clinical health check-up screening are divided into test group and matched group at random, and advance copy is invented fat personnel's antiobesity action.Test group, matched group routine blood test, biochemical indicator are all in range of normal value; Liver, kidney function test there is no unusually, see Table 3.
Table 3 test group, matched group physiochemical indice testing result (x scholar s)
Body weight before and after table 4 experiment, waistline, hip circumference, body fat total amount measurement result (x ± s)
Behind the trial edition product, volunteer's weight loss, waistline reduces, and hip circumference reduces, and body fat total amount reduces, and relatively preceding with test, difference all has statistical significance (P＜0.01); And test back body weight, waistline, hip circumference, body fat total amount minimizing value test group are all greater than matched group, and difference has statistical significance (P＜0.01 or P＜0.05).
Subcutaneous fat thickness measuring result (mm) before and after table 5 experiment (x ± s)
The test group subcutaneous fat thickness descend respectively all be less than test before, difference has statistical significance (P＜0.01); Fat thickness minimizing value test group is greater than matched group before and after the test, and difference has statistical significance (P＜0.05).
This result of study shows, the experimenter is keeping under original life and the dietary habit, take continuously and tried thing 35 days, its body weight, waistline, hip circumference, body fat total amount, each point subcutaneous fat thickness all have minimizing, and test back experimenter's exercise tolerance does not descend, and experimenter's every clinical symptoms, index there is no unusually before and after the test.The present invention can promote the fatty acyl group transhipment, thereby promotes lipid metabolism, reduces the fat mass of various tissues, reaches the purpose of fat-reducing slimming.
Acute toxicity test proves:
The fine graceful capsule acute toxic reaction in the awkward Sheng Kang source, land of this preparation of mouse stomach.Method: the dosage with 20g/kg.bw is irritated stomach, continuous 2 weeks, growth promoter, body constitution amount and the main organs index variation of observing mice.Mice is observed 14d after irritating stomach on an empty stomach, mice there is no poisoning symptom, does not have dead.Tried thing to its mouse oral maximum tolerated dose MTD〉20.Og/kg.BW, the nontoxic level in true border.Conclusion is a comparison safety for using in the fine graceful capsule clinical application scope in Sheng Kang source, preparation of the present invention land.
Table 6: the variation of chmice acute toxic reaction test main organs (x ± s, n=10)
| Group | Liver | Spleen | Gonad | Kidney |
| Normal control | ?6.30±0.15 | ?0.66±0.06 | 2.45±0.13 | 1.86±0.07 |
| The administration group | ?6.24±0.12 | 0.67±0.03 | 2.41±0.08 | 1.88±0.05 |
Acute toxicity test proves that pharmaceutical composition of the present invention is not observed toxicity.
Pharmaceutical composition of the present invention finds to have the effect of fat-reducing by experiment with human feeding trial, and pharmaceutical composition acute toxic reaction of the present invention test do not observe toxic reaction, illustrates that pharmaceutical composition of the present invention is safely and effectively.
The present invention compares with existing external preparation, has following advantage, and pharmaceutical composition of the present invention is not for containing the pure Chinese medicinal preparation of toxicity medical material, has that curative effect is obvious, cost is low, curative effect is high, instant effect, characteristics such as have no side effect.
Obviously, according to foregoing of the present invention,,, can also make modification, replacement or the change of various ways not breaking away under the above-mentioned basic fundamental thought of the present invention prerequisite according to the ordinary skill knowledge and the customary means of this area.The specific embodiment of form is described in further detail foregoing of the present invention again by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
The specific embodiment
Below by concrete embodiment technical scheme of the present invention is further described, the embodiment that wherein exemplifies only is to explanation of the present invention, and does not limit protection scope of the present invention.
Embodiment 1
Prescription: L-carnitine 130g, Rhizoma Alismatis extract 75g, Herb Gynostemmae Pentaphylli extract 79g, tea polyphenols 65g, Folium Nelumbinis extract 74g, dextrin 74g, magnesium stearate 3g.The raw material mix homogeneously adds suitable adjuvant dextrin, magnesium stearate again, sieves, and pours into capsule, makes capsule.
Embodiment 2
Prescription: L-carnitine 110g, Rhizoma Alismatis extract 85g, Herb Gynostemmae Pentaphylli extract 84g, tea polyphenols 75g, Folium Nelumbinis extract 69g, dextrin 74g, magnesium stearate 3g.The raw material mix homogeneously adds suitable adjuvant dextrin, magnesium stearate again, sieves, and tabletting makes tablet.
Embodiment 3
Prescription: L-carnitine 140g, Rhizoma Alismatis extract 65g, Herb Gynostemmae Pentaphylli extract 89g, tea polyphenols 70g, Folium Nelumbinis extract 64g, dextrin 69g, magnesium stearate 3g.The raw material mix homogeneously adds suitable adjuvant dextrin, magnesium stearate again, sieves, and granulates, and makes granule.
Embodiment 4
Prescription: L-carnitine 100g, Rhizoma Alismatis extract 90g, Herb Gynostemmae Pentaphylli extract 85g, tea polyphenols 75g, Folium Nelumbinis extract 94g, dextrin 53g, magnesium stearate 3g.The raw material mix homogeneously adds suitable adjuvant dextrin, magnesium stearate again, sieves, and pours into capsule, makes capsule.
Embodiment 5
Prescription: L-carnitine 120g, Rhizoma Alismatis extract 85g, Herb Gynostemmae Pentaphylli extract 79g, tea polyphenols 55g, Folium Nelumbinis extract 84g, dextrin 74g, magnesium stearate 3g.The raw material mix homogeneously adds suitable adjuvant dextrin, magnesium stearate again, sieves, and granulates, and makes granule.
Embodiment 6
Prescription: L-carnitine 130g, Rhizoma Alismatis extract 75g, Herb Gynostemmae Pentaphylli extract 79g, tea polyphenols 65g, Folium Nelumbinis extract 74g, dextrin 74g, magnesium stearate 3g.The raw material mix homogeneously adds suitable adjuvant dextrin, magnesium stearate again, sieves, and tabletting makes tablet.
Embodiment 7
Prescription: L-carnitine 130g, Rhizoma Alismatis extract 75g, Herb Gynostemmae Pentaphylli extract 79g, tea polyphenols 65g, Folium Nelumbinis extract 74g.The raw material mix homogeneously adds and heats up in a steamer the water dilution in right amount, and filtration, fill make oral liquid.
Claims (3)
1. pharmaceutical composition with weight losing function is characterized in that: compositions is to be the oral formulations made of raw material composition or to be the oral formulations that raw material is made with L-carnitine Rhizoma Alismatis extract, tea polyphenols, Folium Nelumbinis extract with L-carnitine, Rhizoma Alismatis extract, Herb Gynostemmae Pentaphylli extract, Folium Camelliae sinensis extract tea polyphenols, Folium Nelumbinis extract; Wherein the composition percentage by weight is: L-carnitine 10-50%, Rhizoma Alismatis extract 5-30%, Herb Gynostemmae Pentaphylli extract 10-50%, tea polyphenols 5-30%, Folium Nelumbinis extract 5-30%; Adding an amount of adjuvant makes various dosage forms and comprises tablet, capsule, granule or oral liquid.
2. the pharmaceutical composition with weight losing function according to claim 1, it is characterized in that: primary raw material consists of: L-carnitine 20-35%, Rhizoma Alismatis extract 5-10%, Herb Gynostemmae Pentaphylli extract 10-20%, tea polyphenols 10-15%, Folium Nelumbinis extract 5-15%.
3. pharmaceutical composition according to claim 1 is characterized in that: the health food for preparing weight losing function with this medicine components and cooperation dosage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101367029A CN102205011A (en) | 2011-05-25 | 2011-05-25 | Medicinal composition with weight loss function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101367029A CN102205011A (en) | 2011-05-25 | 2011-05-25 | Medicinal composition with weight loss function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102205011A true CN102205011A (en) | 2011-10-05 |
Family
ID=44694254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101367029A Pending CN102205011A (en) | 2011-05-25 | 2011-05-25 | Medicinal composition with weight loss function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102205011A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102511870A (en) * | 2011-12-29 | 2012-06-27 | 山西汉波食品股份有限公司 | Thickened red jujube pulp beneficial to losing weight |
| CN103284146A (en) * | 2013-05-16 | 2013-09-11 | 汤臣倍健股份有限公司 | L-carnitine tea polyphenol tablet and preparation method thereof |
| CN103284039A (en) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | Weight-reducing composition and preparation method thereof |
| CN103504298A (en) * | 2013-09-25 | 2014-01-15 | 海南正康药业有限公司 | Health food with weight-reducing function |
| CN103690819A (en) * | 2013-12-31 | 2014-04-02 | 庞会心 | Traditional Chinese medicinal composition capable of preventing and treating cardiovascular and cerebrovascular diseases and with weight reducing function |
| CN103859389A (en) * | 2012-12-14 | 2014-06-18 | 梁三妹 | Weight-reducing health-care product and preparation method thereof |
| CN104188037A (en) * | 2014-09-29 | 2014-12-10 | 天津市聚星康华医药科技有限公司 | Composite L-carnitine beverage |
| CN104415188A (en) * | 2013-08-19 | 2015-03-18 | 宣城柏维力生物工程有限公司 | L-carnitine tea polyphenol capsule and preparation method thereof |
| CN104688958A (en) * | 2015-03-18 | 2015-06-10 | 遵义陆圣康源科技开发有限责任公司 | Drug combination having function of losing weight |
| CN105031042A (en) * | 2015-06-26 | 2015-11-11 | 天津铸源健康科技集团有限公司 | Medicinal composition having weight-loss function and application of medicinal composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101618034A (en) * | 2009-07-19 | 2010-01-06 | 梁木鸿 | Capsule with effect of weight reducing and preparation technology thereof |
-
2011
- 2011-05-25 CN CN2011101367029A patent/CN102205011A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101618034A (en) * | 2009-07-19 | 2010-01-06 | 梁木鸿 | Capsule with effect of weight reducing and preparation technology thereof |
Non-Patent Citations (1)
| Title |
|---|
| 《中国野生植物资源》 20021231 贺占魁；等 中国减肥植物资源初步研究 33－36 1－3 第21卷, 第6期 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102511870A (en) * | 2011-12-29 | 2012-06-27 | 山西汉波食品股份有限公司 | Thickened red jujube pulp beneficial to losing weight |
| CN103859389A (en) * | 2012-12-14 | 2014-06-18 | 梁三妹 | Weight-reducing health-care product and preparation method thereof |
| CN103859389B (en) * | 2012-12-14 | 2016-12-07 | 布伟年 | A kind of slimming health product and preparation method thereof |
| CN103284039A (en) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | Weight-reducing composition and preparation method thereof |
| CN103284146A (en) * | 2013-05-16 | 2013-09-11 | 汤臣倍健股份有限公司 | L-carnitine tea polyphenol tablet and preparation method thereof |
| CN104415188A (en) * | 2013-08-19 | 2015-03-18 | 宣城柏维力生物工程有限公司 | L-carnitine tea polyphenol capsule and preparation method thereof |
| CN103504298A (en) * | 2013-09-25 | 2014-01-15 | 海南正康药业有限公司 | Health food with weight-reducing function |
| CN103690819A (en) * | 2013-12-31 | 2014-04-02 | 庞会心 | Traditional Chinese medicinal composition capable of preventing and treating cardiovascular and cerebrovascular diseases and with weight reducing function |
| CN104188037A (en) * | 2014-09-29 | 2014-12-10 | 天津市聚星康华医药科技有限公司 | Composite L-carnitine beverage |
| CN104688958A (en) * | 2015-03-18 | 2015-06-10 | 遵义陆圣康源科技开发有限责任公司 | Drug combination having function of losing weight |
| CN105031042A (en) * | 2015-06-26 | 2015-11-11 | 天津铸源健康科技集团有限公司 | Medicinal composition having weight-loss function and application of medicinal composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205011A (en) | Medicinal composition with weight loss function | |
| KR100645385B1 (en) | Composition for anti-obesity | |
| US20060263459A1 (en) | Sea Buckthorn Compositions and Associated Methods | |
| JP2009511468A5 (en) | ||
| CN102727586A (en) | Composition for preventing and treating diabetes | |
| JP2021501119A (en) | Visceral fat obesity prevention, amelioration or therapeutic composition containing Danshen extract | |
| CN101461896A (en) | Chinese medicinal composition assistant for reducing blood fat and preparation method thereof | |
| CN101897925B (en) | Medicinal composition for treating metabolic syndrome | |
| CN103463407B (en) | Reason machine Jiangtang capsule | |
| KR101511364B1 (en) | Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract | |
| JP2019513693A (en) | Composition for amelioration of female menopausal symptoms comprising mandala mochi extract | |
| CN109549207A (en) | A kind of Traditional Chinese medicine compound health food and preparation method thereof with effect of weight reducing | |
| CN108079217A (en) | One kind is made light of one's life by commiting suicide ball | |
| CN110720527A (en) | Traditional Chinese medicine weight-losing tea | |
| CN109316565A (en) | A kind of blood-fat reducing composition and its preparation method and application | |
| CN1935247A (en) | Medicinal composition for treating adiposis or hyperlipemia | |
| CN112384235A (en) | Composition for preventing or treating obesity comprising natural mixed extract | |
| TWI440465B (en) | Herbal extract mixture for reducing blood lipid and a combination thereof | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN110693936B (en) | Traditional Chinese medicine composition for reducing uric acid and preventing and treating hyperuricemia or gout and application thereof | |
| KR101572311B1 (en) | A composition for preventing or treating obesity comprising 2-amino-2-norbornanecarboxylic acid | |
| KR100450055B1 (en) | Food composition for improving physical constitution containing seeds of bean plants as main components, and food produced therefrom | |
| KR20090027383A (en) | Composition for preventing or treating hyperlipidemia | |
| KR20040089258A (en) | Composition for treating obesity and constipation containing extract of pine needle, green tea and black tea as an active ingredient | |
| CN105920017B (en) | A kind of medical composition and its use for treating simple obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111005 |